Evidence map›Paper›PMID 36453519›Full record

SynthesisHaematologica2022

Investigational venetoclax combination therapy in acute myeloid leukemia - a systematic review and meta-analysis.

Shai Shimony, Alon Rozental, Jan P Bewersdorf, Aaron D Goldberg, Eytan M Stein, Alyssa A Grimshaw, Richard M Stone, Daniel J DeAngelo, Ofir Wolach, Maximilian Stahl

Abstract readMeta-AnalysisSystematic ReviewLetter
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Haematologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shai ShimonyMedical Oncology, Dana Farber Cancer Institute, Boston, Ma, USA; Rabin Medical Center, Petah Tikva, Israel and Sackler Medical School, Aviv.
Alon RozentalRabin Medical Center, Petah Tikva, Israel and Sackler Medical School, Aviv.
Jan P BewersdorfLeukemia Service, Memorial Sloan Kettering Cancer Center, New York City, NY.
Aaron D GoldbergLeukemia Service, Memorial Sloan Kettering Cancer Center, New York City, NY.
Eytan M SteinLeukemia Service, Memorial Sloan Kettering Cancer Center, New York City, NY.
Alyssa A GrimshawHarvey Cushing/John Hay Whitney Medical Library, Yale University, New Haven, CT.
Richard M StoneMedical Oncology, Dana Farber Cancer Institute, Boston, Ma.
Daniel J DeAngeloMedical Oncology, Dana Farber Cancer Institute, Boston, Ma.
Ofir WolachRabin Medical Center, Petah Tikva, Israel and Sackler Medical School, Aviv.
Maximilian StahlMedical Oncology, Dana Farber Cancer Institute, Boston, Ma. maximilian_stahl@dfci.harvard.edu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5M
NCI NIH HHS P01 CA066996NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bridged Bicyclo Compounds, HeterocyclicLeukemia, Myeloid, AcuteCombined Modality TherapyHumansSulfonamidesBridged Bicyclo Compounds, HeterocyclicSulfonamidesvenetoclax

Identifiers

PMID36453519
PMCPMC9713559

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.